perindopril has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akiel, MA; Alamri, HS; Alghanem, B; Alroqi, F; Barhoumi, T; Boudjelal, M; Mansour, FA; Shaibah, H | 1 |
| Ardiana, M; Harsoyo, PM; Hermawan, HO; Muhammad, AR; Sufiyah, IM; Suryawan, IGR; Zaini, BSI | 1 |
2 other study(ies) available for perindopril and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
SARS-CoV-2 Coronavirus Spike Protein-Induced Apoptosis, Inflammatory, and Oxidative Stress Responses in THP-1-Like-Macrophages: Potential Role of Angiotensin-Converting Enzyme Inhibitor (Perindopril).
Topics: Angiotensin-Converting Enzyme Inhibitors; Apoptosis; Cell Line; COVID-19; COVID-19 Drug Treatment; Humans; Macrophages; Oxidative Stress; Peptidyl-Dipeptidase A; Perindopril; Pyroptosis; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2021 |
Perindopril and losartan attenuate pro-coagulation factors in human adipocytes exposed to SARS-CoV-2 spike protein.
Topics: Adipocytes; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Blood Coagulation Factors; Cardiovascular Agents; COVID-19; Humans; Losartan; Male; Obesity; Perindopril; Plasminogen Activator Inhibitor 1; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Thromboplastin | 2023 |